Deals
CSL is advancing clazakizumab for the treatment of cardiovascular events in end-stage kidney disease and will retain rights over the asset in this indication. Lilly will explore other conditions.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Three IPO aspirants have stepped up at the start of the new year: CinCor Pharma, Amylyx and Applied UV
Korea Economic Daily, published a story saying that Samsung Group was in talks to acquire Biogen. However, Samsung BioLogics stated in a regulatory filing yesterday that the rumor is not true.
Novartis believes Gyroscope’s investigational Phase II gene therapy for geographic atrophy has the potential to become the first therapy that demonstrates sustained efficacy for GA patients.
Pioneers of synthetic biology have rallied together under the development of Senti Biosciences Inc, co-founded and led by Timothy Lu, associate professor of biological engineering, electrical engineering, and computer science at the Massachusetts Institute of Technology.
Under the terms of the deal, Sanofi is paying Amunix $1 billion up front and up to $225 million in various development milestone payments.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
Mergers and acquisitions are part of the lifeblood of the pharmaceutical industry, as companies flex their pocketbooks to acquire pipelines and talent to bolster and complement their own programs.
The year kicked off with a bang as multiple companies raced to a public listing.
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
Shares of BeiGene have fallen 16% in China in part due to concerns over potential U.S. sanctions against Chinese biotech companies.